TDOC: financial statements from SEC — TradeAlmanac

TDOC

Teladoc Health, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31 Dec 2025	31 Dec 2024
Revenue	2.53B	2.57B
Cost of revenue	772M	751M
Research and development	278M	307M
Selling, general and administrative	432M	435M
Operating expenses	2.79B	3.59B
Operating income	−263M	−1.02B
Pre-tax income	−236M	−994M
Income tax	−35M	8M
Net income	−200M	−1.00B
Earnings per share	−1.14	−5.87
Earnings per share, diluted	−1.14	−5.87
Weighted average shares	176M	171M
Weighted average shares, diluted	176M	171M

Balance sheet

Metric	31 Mar 2026	31 Dec 2025	30 Sept 2025	30 Jun 2025	31 Mar 2025	31 Dec 2024	30 Sept 2024	30 Jun 2024
Cash and equivalents	751M	781M	726M	680M	1.19B	1.30B	1.24B	1.16B
Receivables	214M	193M	211M

Cash flow

Metric	31 Dec 2025	31 Dec 2024
Operating cash flow	294M	294M
Share-based compensation	80M	146M
Capital expenditure	9M	11M
Investing cash flow	−266M	−124M
Financing cash flow	−552M	8M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator